MAGNETO
Research type
Research Study
Full title
89Zr-belantamab PET-CT imaging to detect myeloma
IRAS ID
1007735
Contact name
Karthik Ramasamy
Contact email
Sponsor organisation
Oxford University Hospitals NHS Foundation Trust
ISRCTN Number
ISRCTN25958282
Research summary
This study is investigating whether a new type of imaging scan can be used to assess patients with multiple myeloma, which is a cancer that mainly involves the bones. The scan involves injecting patients with a small dose of a radioactive antibody (radiotracer) 89Zr-belantamab. The radiotracer is made from a drug that is used to treat myeloma. It is expected to selectively accumulate in the cancer and measured using a PET scanner. In this study, patients who have myeloma detectable by other types of imaging scan will be recruited. Up to 19 patients will be injected with the radiotracer twice and scanned up to 12 times over the course of 14-21 days to help determine to which degree and how quickly the radiotracer accumulates in the myeloma tumours. This is useful as, whilst not therapeutic, it will help understand the best time for imaging patients and also give an indication of how much radiation the patients are exposed to by the test.
REC name
North West - Haydock Research Ethics Committee
REC reference
23/NW/0315
Date of REC Opinion
5 Feb 2024
REC opinion
Further Information Favourable Opinion